Report Content
Chapter 1 Methodology & Scope
1.1 Definitions and forecast parameters
1.1.1 Definitions
1.1.2 Methodology and forecast parameters
1.2 Data sources
1.2.1 Secondary
1.2.2 Primary
Chapter 2 Executive Summary
2.1 North America bioreactors industry summary, 2017-2028
2.1.1 Country trends
2.1.2 Product type trends
2.1.3 Cell trends
2.1.4 Molecule trends
2.1.5 Usage trends
2.1.6 End-user trends
Chapter 3 Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017-2028 (USD Million)
3.3 Major factor analysis
3.3.1 Drivers
3.3.1.1 Growing pharmaceutical and biotechnology industry in the region
3.3.1.2 Rising government initiatives in the region
3.3.1.3 Technological advancements in bioprocessing systems
3.3.1.4 Rising demand for vaccines and cell-targeted therapies
3.3.2 Industry pitfalls and challenges
3.3.2.1 Limitations associated with single-use bioreactors
3.3.2.2 Concerns regarding extractables and leachables
3.3.2.3 Stringent regulatory framework
3.4 Analysis of COVID-19 impact on the industry
3.5 Porter’s analysis
3.6 Competition review, 2021
3.7 PEST analysis
Chapter 4 North America Bioreactors Market, By Product Type
4.1 Market trends
4.2 Single use
4.2.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
4.3 Reusable
4.3.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
Chapter 5 North America Bioreactors Market, By Cell
5.1 Market trends
5.2 Mammalian cells
5.2.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
5.3 Bacterial cells
5.3.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
5.4 Yeast cells
5.4.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
5.5 Others
5.5.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
Chapter 6 North America Bioreactors Market, By Molecule
6.1 Market trends
6.2 Monoclonal antibodies
6.2.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
6.3 Vaccines
6.3.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
6.4 Recombinant proteins
6.4.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
6.5 Stem cells
6.5.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
6.6 Gene therapy
6.6.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
6.7 Others
6.7.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
Chapter 7 North America Bioreactors Market, By Usage
7.1 Market trends
7.2 Developmental, pre-clinical & clinical
7.2.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
7.3 Commercial production
7.3.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
Chapter 8 North America Bioreactors Market, By End-user
8.1 Market trends
8.2 R&D organizations
8.2.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
8.3 Biopharma manufacturers
8.3.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
8.4 Contract manufacturing organizations (CMOs)
8.4.1 Market estimates and forecast, by country, 2017-2028 (USD Million)
Chapter 9 North America Bioreactors Market, By Country
9.1 Market trends
9.2 U.S.
9.2.1 Market estimates and forecast, by product type, 2017-2028 (USD Million)
9.2.2 Market estimates and forecast, by cell, 2017-2028 (USD Million)
9.2.3 Market estimates and forecast, by molecule, 2017-2028 (USD Million)
9.2.4 Market estimates and forecast, by usage, 2017-2028 (USD Million)
9.2.5 Market estimates and forecast, by end-user, 2017-2028 (USD Million)
9.3 Canada
9.3.1 Market estimates and forecast, by product type, 2017-2028 (USD Million)
9.3.2 Market estimates and forecast, by cell, 2017-2028 (USD Million)
9.3.3 Market estimates and forecast, by molecule, 2017-2028 (USD Million)
9.3.4 Market estimates and forecast, by usage, 2017-2028 (USD Million)
9.3.5 Market estimates and forecast, by end-user, 2017-2028 (USD Million)
Chapter 10 Company Profiles
10.1 Applikon Biotechnology, Inc. (Getinge)
10.1.1 Business overview
10.1.2 Financial data
10.1.3 Product landscape
10.1.4 Strategic outlook
10.2 Bbi-biotech
10.2.1 Business overview
10.2.2 Financial data
10.2.3 Product landscape
10.2.4 Strategic outlook
10.3 Cellexus Limited
10.3.1 Business overview
10.3.2 Financial data
10.3.3 Product landscape
10.3.4 Strategic outlook
10.4 CerCell Aps
10.4.1 Business overview
10.4.2 Financial data
10.4.3 Product landscape
10.4.4 Strategic outlook
10.5 Eppendorf AG
10.5.1 Business overview
10.5.2 Financial data
10.5.3 Product landscape
10.5.4 Strategic outlook
10.6 Cytiva (Danaher Corporation)
10.6.1 Business overview
10.6.2 Financial data
10.6.3 Product landscape
10.6.4 Strategic outlook
10.7 GEA Group Aktiengesellschaft
10.7.1 Business overview
10.7.2 Financial data
10.7.3 Product landscape
10.7.4 Strategic outlook
10.8 Merck Group
10.8.1 Business overview
10.8.2 Financial data
10.8.3 Product landscape
10.8.4 Strategic outlook
10.9 Pierre Guerin SAS
10.9.1 Business overview
10.9.2 Financial data
10.9.3 Product landscape
10.9.4 Strategic outlook
10.10 Sartorius Stedim Biotech Group
10.10.1 Business overview
10.10.2 Financial data
10.10.3 Product landscape
10.10.4 Strategic outlook
10.11 Solaris Biotech Solutions
10.11.1 Business overview
10.11.2 Financial data
10.11.3 Product landscape
10.11.4 Strategic outlook
10.12 Thermo Fisher Scientific Inc.
10.12.1 Business overview
10.12.2 Financial data
10.12.3 Product landscape
10.12.4 Strategic outlook
10.13 Solida Biotech
10.13.1 Business overview
10.13.2 Financial data
10.13.3 Product landscape
10.13.4 Strategic outlook